New paradigms for treatment-resistant depression

摘要: Clinical depression is a serious mental disorder characterized by low mood, anhedonia, loss of interest in daily activities, and other symptoms, associated with severe consequences including suicide increased risk cardiovascular events. Depression affects nearly 15% the population. The standard care for last 50 years has focused on monoamine neurotransmitters, such treatments as selective serotonin reuptake inhibitors (SSRIs) serotonin–norepinephrine (SNRIs). However, these have significant limitations: they can take weeks before showing mood-altering effects, only one to two out ten patients shows clinical effects beyond those placebo. A major paradigm shift research into treatment underway, based promising results glutamatergic NMDA receptor antagonist ketamine. Further demonstrated significance pathways association this system stress pathway magnesium homeostasis. Treatment antagonists shown ability sprout new synaptic connections reverse stress-induced neural changes, opening up territory development drugs meet unmet need depression.